TY - JOUR
T1 - Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis
AU - Strati, Paolo
AU - Abdelrahim, Maen
AU - Selamet, Umut
AU - Page, Valda D.
AU - Pierce, Sherry A.
AU - Verstovsek, Srdan
AU - Abudayyeh, Ala
N1 - Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Recent evidence suggests that renal dysfunction may be a direct consequence of primary myelofibrosis (PMF). We performed a retrospective analysis of 100 patients with previously untreated PMF, receiving frontline treatment with single agent ruxolitinib, and compared them to 105 patients, receiving frontline treatment with a non-ruxolitinib-based therapy, matched by age, sex, DIPSS plus, and estimated glomerular filtration rate (eGFR). Use of ruxolitinib associated with a significantly higher rate of renal improvement (RI) > 10% (73% vs 50%, p = 0.01) confirmed on multivariate analysis (MVA) [odds ratio 3, 95% confidence interval (CI) 1.6–5.5, p < 0.001]. After a median follow-up of 41 months (range, 1–159 months), median failure-free survival (FFS) was 14 months (range, 1–117 months). Achievement of a RI > 10% maintained its independent association with prolonged FFS on MVA (hazard ratio 1.4, 95% CI 1.1–2, p = 0.02). Ruxolitinib can significantly improve renal function in patients with PMF, significantly impacting failure-free survival.
AB - Recent evidence suggests that renal dysfunction may be a direct consequence of primary myelofibrosis (PMF). We performed a retrospective analysis of 100 patients with previously untreated PMF, receiving frontline treatment with single agent ruxolitinib, and compared them to 105 patients, receiving frontline treatment with a non-ruxolitinib-based therapy, matched by age, sex, DIPSS plus, and estimated glomerular filtration rate (eGFR). Use of ruxolitinib associated with a significantly higher rate of renal improvement (RI) > 10% (73% vs 50%, p = 0.01) confirmed on multivariate analysis (MVA) [odds ratio 3, 95% confidence interval (CI) 1.6–5.5, p < 0.001]. After a median follow-up of 41 months (range, 1–159 months), median failure-free survival (FFS) was 14 months (range, 1–117 months). Achievement of a RI > 10% maintained its independent association with prolonged FFS on MVA (hazard ratio 1.4, 95% CI 1.1–2, p = 0.02). Ruxolitinib can significantly improve renal function in patients with PMF, significantly impacting failure-free survival.
KW - PMF
KW - Renal function
KW - Ruxolitinib
UR - http://www.scopus.com/inward/record.url?scp=85065833300&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065833300&partnerID=8YFLogxK
U2 - 10.1007/s00277-019-03708-9
DO - 10.1007/s00277-019-03708-9
M3 - Article
C2 - 31093708
AN - SCOPUS:85065833300
SN - 0939-5555
VL - 98
SP - 1611
EP - 1616
JO - Annals of Hematology
JF - Annals of Hematology
IS - 7
ER -